The Latest
-
Andrew Harnik via Getty Images
At Senate hearing, lawmakers express dissatisfaction with RFK Jr.’s vaccine moves
Robert F. Kennedy Jr. faced criticism Thursday even from Republican lawmakers over changes to federal vaccine policy as well as a leadership crisis at the CDC.
-
Stock via Getty Images
International appeal: Europe and UK lure US scientists with financial incentives
With slashed budgets and decimated research programs, American scientists are increasingly looking for career opportunities abroad.
-
Sergey Balakhnichev via Getty Images
Why drugmakers may need to borrow from quantum theory to confront tariff and pricing threats
With so many unknowns surrounding regulatory and policy shifts, pharma companies might need to consider fundamental changes to how they operate, a Deloitte analyst said.
-
Stock via Getty Images
How AI advances will shape the drugmaker of the future
An AI revolution is taking place, and leaders from tech to Big Pharma are forecasting what drugmakers of the future will look like.
-
Joe Raedle via Getty Images
FDA approves updated COVID boosters, but narrows use
In a post on X, HHS Secretary Robert F. Kennedy said the FDA has cleared vaccines from Pfizer, Moderna and Novavax for use in "high risk" individuals.
Updated Aug. 27, 2025 -
Eva Marie Uzcategui via Getty Images
How a SpaceX mission could speed drug discoveries on Earth
Research enabled by blasting off into space could lead to better treatments for diseases such as ALS and Parkinson’s.
-
Stock via Getty Images
A brewing GLP-1 showdown, from Big Pharma pills to a biotech implant
Newcomers looking for a way into the obesity space are developing unique methods to snag market share.
-
Stock via Getty Images
AbbVie dives back into the neuro pool with a $1.2B psychedelics play
Following a major clinical failure last year, AbbVie’s purchase of a psychedelic depression treatment has the potential to revive a touch-and-go market.
-
Sarah Silbiger via Getty Images
Why an FDA decision for a new drug could ripple through the ultra-rare disease space
All eyes are on Stealth BioTherapeutics as it awaits a long-delayed approval for its first-in-class treatment for Barth syndrome.
-
Anna Moneymaker via Getty Images
FDA’s new accelerated pathway could open pharma up to risks, as well as benefits
Faster review times will leave drugmakers vulnerable to litigation, while new Trump administration priorities add more uncertainty in the drug approval process.
-
Justin Sullivan via Getty Images
And just like that... pharma’s breakups reveal pain points in cancer R&D
Biotech tie-ups with Gilead, Genetech and Ipsen that have recently been let go.
-
Stock via Getty Images
The biggest Big Pharma losers in the first half of 2025
What goes up must come down — here are the major drugs falling the hardest at the top companies so far this year.
-
Andrew Harnik via Getty Images
MAHA leaders may take aim at pharma DTC advertising
RFK Jr. has his sights set on increasing advertising enforcement against pharmas, but may not come down as hard on the industry as previously thought.
-
Stock via Getty Images
Q&AIn cell therapy, cost is a hot issue. The industry might need a cold solution.
The logistical linchpin of cryopreservation could make a challenging space more accessible.
-
Mario Tama / Getty via Getty Images
Despite FDA ruling, compounded GLP-1s are still giving Novo and Lilly headaches on the market
Copycat weight loss drugs were supposed to be pulled from the market, but pharmacies have found a loophole.
-
Stock via Getty Images
Biopharma layoffs rise as drugmakers tighten belts and reorganize
Contrary to a predicted slowdown, 2025’s layoffs are outpacing 2024.
-
Permission granted by Merck KGaA
Merck KGaA ventures into new territory in the US
How the president of EMD Serono, Merck KGaA, Darmstadt, Germany’s U.S. arm, is leading the charge to “double down” on new innovation.
-
Alex Wong via Getty Images
With scrapped mRNA funding, a vaccine maker finds a silver lining
While mRNA is suffering the brunt of the MAHA movement with $500 million in funding cuts, other vaccine makers could fill some of that void.
-
Anna Moneymaker via Getty Images
With FDA PreCheck, drugmakers may get a manufacturing boost
The newly announced program targeting domestic manufacturing is the latest Trump administration move to ramp up drugmaking in the U.S.
-
Stock via Getty Images
Puerto Rico’s ongoing journey from manufacturing hub to innovation enterprise
Biotechs are coming to the island as tariffs threaten overseas drug exports, and finding Puerto Rico is more than just a leading manufacturing hub.
-
Scott Olson via Getty Images
3 ways the GLP-1 market has changed shape this year
Novo Nordisk and Eli Lilly’s quarterly earnings revealed shifting dynamics in the lucrative obesity space.
-
Stock via Getty Images
Are stem cell therapies ready for pharma’s prime time?
Stem cell therapies are thriving on the fringes of healthcare — but science-backed treatments are also poised to make an impact in pharma R&D.
-
Stock via Getty Images
As gene therapies falter on the market, this biopharma is aiming to defy the odds
After a strong launch for its cancer gene therapy, Ferring Pharmaceuticals is setting the stage for long-term growth.
-
Permission granted by AstraZeneca
Q&AInside AstraZeneca’s long-game strategy in lung cancer
New long-term results for Tagrisso in EGFR-mutated non-small cell lung cancer showcase a precision approach the company has honed for decades.
-
Andrew Harnik via Getty Images
PBM reform was dropped from Trump’s spending bill. It could have saved billions.
The Senate nixed a provision to “delink” drug list prices from compensation for PBMs and other drug middlemen days before its passage.
